<DOC>
	<DOCNO>NCT01885494</DOCNO>
	<brief_summary>AFF008E set-up ass long term effect 4 PD01A vaccination apply AFF008 regard safety well immunological- , radiological clinical activity . Accordingly , AFF008E , vaccine dose apply . Instead , patient participate AFF008 assess another 52 week occasion 4 quarterly visit . This offer patient receive PD01A vaccination also patient serve control AFF008 . Thus , AFF008E ensure standardize controlled management individual receive PD01A part AFF008 , Phase I study analyze first time human first class candidate .</brief_summary>
	<brief_title>AFF008E : Observational Phase 1b Follow-up Extension Study Patients With Parkinson 's Disease After Immunization With AFFITOPEÂ® PD01A</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Written inform consent sign dated patient Participation AFF008 History questionable compliance visit schedule ; patient expect complete clinical trial Participation active treatment phase another clinical trial except AFF008 within 13 week Visit 1 whole study duration</criteria>
	<gender>All</gender>
	<minimum_age>41 Years</minimum_age>
	<maximum_age>66 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>